Triptolide-d3

CAT:
804-HY-32735S
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Triptolide-d3 - image 1

Triptolide-d3

  • UNSPSC Description:

    Triptolide-d3 is the deuterium labeled Triptolide. Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor[1][2][3][4][5][6].
  • Target Antigen:

    Apoptosis; Isotope-Labeled Compounds; NF-κB
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Apoptosis;NF-κB;Others
  • Field of Research:

    Cancer
  • Purity:

    89.82
  • Solubility:

    DMSO : 25 mg/mL (ultrasonic;warming)
  • Smiles:

    C[C@@]12[C@@]34[C@]5([C@@H]([C@@]6([C@](O6)([H])[C@]3([H])O4)C(C)C)O)[C@@](C[C@@]1([2H])C7=C(C(OC7([2H])[2H])=O)CC2)([H])O5
  • Molecular Weight:

    363.42
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Ganguly S, et al. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget. 2015 Oct 13;6(31):31767-79.|[3]Huang M, et al. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther. 2013 Feb;12(2):184-94.|[4]Xu P, et al. Triptolide Inhibited Cytotoxicity of Differentiated PC12 Cells Induced by Amyloid-Beta25-35 via the Autophagy Pathway. PLoS One. 2015 Nov 10;10(11):e0142719.|[5]Kong LL, et al. Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. Sci Rep. 2015 Jul 2;5:11747.|[6]Zhang W, et al. Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism. Int J Mol Sci. 2016 Dec 19;17(12). pii: E2139.|[7]Cai J, et al. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J Exp Clin Cancer Res. 2021;40(1):190. Published 2021 Jun 9.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -20°C (Powder, protect from light, stored under nitrogen)
  • Clinical Information:

    No Development Reported